Deciphering the Synergistic Crash
BRASH syndrome is a clinical entity where a combination of AV nodal-blocking agents and hyperkalemia triggers a life-threatening cycle of bradycardia, shock, and renal failure.
Synergy Simulator
Interact with the physiological variables to observe the synergistic effect. Note how the combination of moderate AV-blocker use and rising Potassium causes a rapid heart rate collapse.
Cardiac output is currently compensated.
Clinical Prediction: Heart Rate (BPM)
The Vicious Cycle
Pathophysiology in BRASH isn’t static; it’s a feedback loop where each organ failure accelerates the others.
Trigger
Hypovolemia or medication changes reduce perfusion.
Renal Lag
AKI leads to decreased clearance and Potassium accumulation.
Synergy
Hyperkalemia sensitizes the heart to AV-nodal blockade.
The Crash
Low HR causes further AKI, trapping more K+ in the loop.
Therapeutic Objectives
Effective management of BRASH syndrome requires a simultaneous, three-pronged approach to break the vicious cycle and restore systemic stability.
Metabolic Correction
Correction of hyperkalemia: Reducing potassium levels is vital to decrease the heart’s sensitivity to AV-nodal blocking agents.
Hemodynamic Support
Support for bradycardia and hypotension: Maintaining perfusion pressure to the kidneys is essential to prevent worsening AKI.
Etiologic Management
Treating triggering events: This includes correcting hypovolemia and discontinuing culprit AV-nodal blocking medications.
Transvenous Pacing
Necessary for severe bradycardia that is refractory to medical management. It bridges the patient until electrolytes and medications are cleared.
Hemodialysis
The definitive method for rapid potassium removal in patients with advanced renal failure and life-threatening hyperkalemia.
